[ad_1]
The first vaccine developed by the company is still in the testing phase.
Sanofi and the American company Translate Bio are developing a vaccine based on information RNA technology.
The objective of the first and second stages of the test is to verify that the vaccine is not dangerous and to provide initial information on its effectiveness.
The third stage involves a larger number of participants to determine the effectiveness of the vaccine.
The first trials will involve 415 people, with initial results expected in the third trimester.
Information RNA technology is also used in vaccines developed by Pfizer and BioNTech and Moderna, which are already approved in the European Union, the United States, and other countries.
The previous candidate vaccine, developed by Sanofi in collaboration with the British company GSK, is manufactured using recombinant proteins, but the development of the vaccine is several months behind schedule and only phase 2 trials are currently underway.
Sanofi agreed to help produce COVID-19 vaccines developed by Pfizer and Johnson & Johnson.
If you have any questions about the COVID-19 vaccine, please send them to our editorial staff by email. email address [email protected].
[ad_2]
